The Safety and Efficacy of Redsenol-1 Plus on Cancer-related Fatigue in Adults

Fatigue Clinical Trial

Official title:

A Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of Redsenol-1 Plus on Cancer-related Fatigue in Adults

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05664009
• Other study ID #: 22EPRSZ03
• Status: Recruiting
• Phase: Phase 2
• Start date: May 30, 2023
• Est. completion date: June 2025

Study information

• Verified date: April 2024
• Source: Canada Royal Enoch Phytomedicine Co., Ltd.
• Contact: Erin Lewis, PhD
• Phone: 1-226-242-4551
• Email: elewis[@]kgkscience.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the safety and efficacy of Redsenol-1 Plus on cancer-related fatigue (CRF) in adults. The change in the severity of CRF from baseline at week 12 will be assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) fatigue subscale, and compared between Redsenol-1 Plus and placebo groups. Additionally, the safety and tolerability of Redsenol-1 Plus, as compared to placebo, will be measured by the occurrence of and/or changes in treatment-emergent adverse events (AEs).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 72
• Est. completion date: June 2025
• Est. primary completion date: May 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Males and females =18 years of age.

2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening

Or,

Females of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

• Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)

• Double-barrier method

• Intrauterine devices

• Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)

• Vasectomy of partner at least 6 months prior to screening

3. Individuals previously diagnosed with cancer and have CRF defined as a score of =4 on the CRF Single-Item Scale (an 11-point scale where 0 is "no fatigue" and 10 is "as bad as it can be")

4. CRF present for at least one month prior to screening

5. Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score =2

6. Hemoglobin level of =110 g/L for females and =129 g/L for males at screening

7. Agrees to maintain current lifestyle habits as much as possible throughout the study depending on ability to maintain the following: diet, medications, supplements, exercise, and sleep and avoid taking new supplements during the study period

9. Provided voluntary, written, informed consent to participate in the study

10. Otherwise healthy as determined by medical history and laboratory results as assessed by Qualified Investigator (QI) while taking into consideration the participant's cancer history

Exclusion Criteria:

1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study

2. Allergy, sensitivity, or intolerance to the investigational product's or placebo's active or inactive ingredients

3. Individuals with any CNS malignancies (e.g., brain or spine) and/or estrogen-receptor positive breast cancer

4. Individuals with other primary causes of fatigue, as assessed by the QI (e.g., diagnosed non-cancer related chronic pain, insomnia/sleep disorders, depression/psychiatric disorders, unstable hypothyroidism, diabetes)

5. Individuals with unstable medical conditions as assessed by the QI

6. Individuals with current untreated/uncontrolled high blood pressure or tachycardia/heart rhythm disorders

7. Individuals with >7.5% HbA1c with treatment for high blood sugar/diabetes or individuals with =6.5% HbA1c without treatment

8. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis

9. History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months

10. Major non-cancer surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI

11. Current use of prescription/OTC medications and/or supplements and food/drinks which may affect the efficacy and/ or safety of the IP (see Sections 7.3.1 and 7.3.2)

12. Alcohol or drug abuse within the last 12 months

13. Frequent (daily) and chronic cannabis users. Occasional (e.g., once per month) cannabis users may be included at the discretion of the QI and if eligible, asked to stop cannabis use for study period

14. Clinically significant abnormal laboratory results at screening as assessed by the QI

15. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI

16. Individuals who are unable to give informed consent

17. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant

18. Individuals who are on active cancer treatment (e.g., radiation, chemotherapy, immunotherapy, target therapy), have completed cancer treatment within one month of baseline, and/or are scheduled to receive further treatment during the study period.

Related Conditions & MeSH terms

• Cancer, Treatment-Related
• Fatigue
• Neoplasms, Second Primary

Intervention

Dietary Supplement:
• Redsenol-1 Plus
Two capsules of Redsenol-1 Plus will be taken three times per day for 12 weeks (84 days).

Other:
• Placebo
Two capsules of Placebo will be taken three times per day for 12 weeks (84 days).

Locations

Country	Name	City	State
Canada	KGK Science Inc.	London	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Canada Royal Enoch Phytomedicine Co., Ltd.	KGK Science Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The change in the severity of cancer-related fatigue from baseline to week 12.	The change in the severity of cancer-related fatigue from baseline to week 12 as assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) fatigue subscale will be compared between Redsenol-1 Plus and placebo.	baseline and 84 days
Secondary	The difference in change of severity of cancer-related fatigue from baseline to weeks 4 and 8.	The difference in change of severity of cancer-related fatigue from baseline to weeks 4 and 8 as assessed by the FACIT-F fatigue subscale will be compared between Redsenol-1 Plus and placebo.	baseline, 28 days, 56 days
Secondary	The difference in change of cancer-related quality of life (QoL) from baseline at weeks 4, 8 and 12.	The difference in change of cancer-related quality of life (QoL) from baseline at weeks 4, 8 and 12 between Redsenol-1 Plus compared to placebo as assessed by the FACIT-F total score.	baseline, 28 days, 56 days, 84 days
Secondary	The difference in change of cancer-related quality of life (QoL) from baseline at weeks 4, 8 and 12.	The difference in change of cancer-related quality of life (QoL) from baseline at weeks 4, 8 and 12 between Redsenol-1 Plus compared to placebo as assessed by the FACIT-F physical well-being (PWB) sub-scale.	baseline, 28 days, 56 days, 84 days
Secondary	The difference in change of cancer-related quality of life (QoL) from baseline at weeks 4, 8 and 12.	The difference in change of cancer-related quality of life (QoL) from baseline at weeks 4, 8 and 12 between Redsenol-1 Plus compared to placebo as assessed by the social well-being (SWB) sub-scale.	baseline, 28 days, 56 days, 84 days
Secondary	The difference in change of cancer-related quality of life (QoL) from baseline at weeks 4, 8 and 12.	The difference in change of cancer-related quality of life (QoL) from baseline at weeks 4, 8 and 12 between Redsenol-1 Plus compared to placebo as assessed by the emotional well-being (EWB) sub-scale.	baseline, 28 days, 56 days, 84 days
Secondary	The difference in change of cancer-related quality of life (QoL) from baseline at weeks 4, 8 and 12.	The difference in change of cancer-related quality of life (QoL) from baseline at weeks 4, 8 and 12 between Redsenol-1 Plus compared to placebo as assessed by the functional well-being (FWB) sub-scale.	baseline, 28 days, 56 days, 84 days
Secondary	The difference in the proportion of participants who have a clinically important change in severity of cancer-related fatigue from baseline to 4 weeks, 8 weeks, and 12 weeks.	The difference in the proportion of participants who have a clinically important change in severity of cancer-related fatigue as assessed by the FACIT-F fatigue subscales from baseline to 4 weeks, 8 weeks, and 12 weeks between Redsenol-1 Plus compared to placebo.	baseline, 28 days, 56 days, 84 days
Secondary	The difference in performance status from baseline to weeks 4, 8, and 12.	The difference in performance status as assessed by the Eastern Cooperative Oncology Group (ECOG) tool from baseline to weeks 4, 8, and 12 between Redsenol-1 Plus compared to placebo.	baseline, 28 days, 56 days, 84 days
Secondary	The difference in mood from baseline to weeks 4, 8, and 12.	The difference in mood as assessed by the Profile of Mood States (POMS) questionnaire from baseline to weeks 4, 8, and 12 between Redsenol-1 Plus compared to placebo.	baseline, 28 days, 56 days, 84 days
Secondary	Incidence of pre-emergent and post-emergent adverse events following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Incidence of pre-emergent and post-emergent adverse events following supplementation with Redsenol-1 Plus or placebo for 12 weeks will be collected at screening and baseline and will be compared to post-emergent AEs to enable identification of AEs that may be potentially related to the investigational product.	84 days
Secondary	Blood pressure at baseline and following supplementation with Redsenol-1 Plus or placebo for 4 weeks, 8 weeks, and 12 weeks.	Blood pressure at baseline and following supplementation with Redsenol-1 Plus or placebo for 4 weeks, 8 weeks, and 12 weeks. Blood pressure will be determined from 3 measurements obtained at least 1 minute apart. One arm will be chosen and used consistently throughout the study. Blood pressure will be checked in both arms at the first examination.	baseline, 4 weeks, 8 weeks, 12 weeks
Secondary	Heart rate at baseline and following supplementation with Redsenol-1 Plus or placebo for 4 weeks, 8 weeks, and 12 weeks.	Heart rate at baseline and following supplementation with Redsenol-1 Plus or placebo will be will be determined from 3 measurements obtained at least 1 minute apart. One arm will be chosen and used consistently throughout the study. Blood pressure will be checked in both arms at the first examination.	baseline, 4 weeks, 8 weeks, 12 weeks
Secondary	Aspartate aminotransferase (AST) measurement following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Aspartate aminotransferase (AST) will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Alanine aminotransferase (ALT) measurement following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Alanine aminotransferase (ALT) will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Alkaline phosphatase (ALP) measurement following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Alkaline phosphatase (ALP) will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Bilirubin measurement following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Total bilirubin will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Creatinine measurement following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Creatinine will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Measurement of electrolytes (Na, K ,Cl) following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Electrolytes will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Measurement of glucose following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Glucose will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Estimated glomerular filtration rate (eGFR) measurement following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Estimated glomerular filtration rate (eGFR) will be measured in blood from study participants at 12 weeks.	84 days
Secondary	White blood cell count measurements following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	White blood cell count with differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils) will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Red blood cell count measurements following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Red blood cell count will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Hemoglobin measurement following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Hemoglobin will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Hematocrit measurement following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Hematocrit will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Platelet count measurement following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Platelet count will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Mean corpuscular volume measurement following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Mean corpuscular volume will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Mean corpuscular hemoglobin measurement following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Mean corpuscular hemoglobin will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Mean corpuscular hemoglobin concentration measurement following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Mean corpuscular hemoglobin concentration will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Red blood cell distribution width measurement following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Red blood cell distribution will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Immature granulocyte measurement following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Immature granulocytes will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Nucleated red blood cell measurement following supplementation with Redsenol-1 Plus or placebo for 12 weeks.	Nucleated red blood cells will be measured in blood from study participants at 12 weeks.	84 days
Secondary	Incidence of adverse events during the follow-up period (weeks 12-16).	Incidence of adverse events during the 4-week follow-up period (weeks 12-16).	112 days